Dual Drug Delivery Systems Based on Porous Fibers Grafted with ZIF67

Metal-organic frameworks (MOFs) have emerged as promising materials for various applications due to their exceptional tunability and high surface area. In recent years, the integration of MOFs with fibers has gained significant attention in the field of drug delivery systems. The combination of MOFs and fibers offers a unique platform for controlled release, targeted therapy, and enhanced drug stability, ultimately revolutionizing the field of therapeutics.<br/>Moreover, researchers have explored the application of dual drug delivery using porous fibers with MOFs in various therapeutic areas, including cancer therapy, antimicrobial treatments, and regenerative medicine. These studies have demonstrated the potential of these systems to overcome drug resistance, reduce side effects, and enhance treatment efficacy by delivering multiple drugs simultaneously.<br/>In this study, we developed porous poly(caprolactone) (PCL) fibers through liquid-liquid phase separation, and then ZIF-67 was grown on the porous PLA fiber through in-situ synthesis. These carriers were investigated the relationship among pore formation, physical properties, and antibacterial activities of the fibers for identifying their potential as drug delivery carriers. Studies have focused on optimizing the synthesis techniques to achieve uniform ZIF67 coatings on the surface of porous PCL fibers.<br/>Suggested dual drug delivery system using porous PCL fibers with ZIF67 are the co-delivery of two drugs including lysozyme and gentamicin with complementary antibacterial effects. By encapsulating dual drugs inside pores of PCL and ZIF67, the dual drug delivery system achieves synergistic effects, improved drug stability, and controlled release kinetics. Furthermore, the selection of appropriate drugs and their optimal ratios play a crucial role in achieving desired antibacterial outcomes.<br/>Overall, the research on dual drug delivery using porous fibers with ZIF67 highlights the potential of these drug carrier systems in achieving controlled release, synergistic effects, and improved antibacterial outcomes. Further advancements in the synthesis techniques, optimization of drug ratios, and comprehensive understanding of the in vivo behavior are crucial to translate these innovative systems into clinical applications and address the challenges associated with their practical implementation.